Influenza viruses cause over 500,000 deaths worldwide 1 and are associated with an annual cost of 12 -14 billion USD in the United States alone considering direct medical and hospitalization expenses and work absenteeism 2 . Animal models are crucial in Influenza A virus (IAV) studies to evaluate viral pathogenesis, host-pathogen interactions, immune responses, and the efficacy of current and/or novel vaccine approaches as well as antivirals. Mice are an advantageous small animal model because their immune system is evolutionarily similar to that found in humans, they are available from commercial vendors as genetically identical subjects, there are multiple strains that can be exploited to evaluate the genetic basis of infections, and they are relatively inexpensive and easy to manipulate. To recapitulate IAV infection in humans via the airways, mice are first anesthetized prior to intranasal inoculation with infectious IAVs under proper biosafety containment. After infection, the pathogenesis of IAVs is determined by monitoring daily the morbidity (body weight loss) and mortality (survival) rate. In addition, viral pathogenesis can also be evaluated by assessing virus replication in the upper (nasal mucosa) or lower (lungs) respiratory tract of infected mice. Humoral responses upon IAV infection can be rapidly evaluated by non-invasive bleeding and secondary antibody detection assays aimed at detecting the presence of total or neutralizing antibodies. Here, we describe the common methods used to infect mice intranasally (i.n) with IAV and evaluate pathogenesis, humoral immune responses and protection efficacy.
Introduction
IAVs are enveloped viruses classified in the Orthomyxoviridae family 3 . They contain eight single-stranded RNA molecules with negative polarity 3 . In humans, IAVs cause seasonal epidemics and occasional pandemics of important consequence when novel viruses are introduced in the human population 4 . Moreover, seasonal IAVs are highly and rapidly transmitted between humans producing an elevated economic loss worldwide every year 2, 5 . IAV symptoms include cough, nasal congestion, fever, malaise, headache, anorexia and myalgia, but the virus can also produce a more severe disease in immunocompromised patients 6 . In fact, the World Health Organization (WHO) calculates that seasonal influenza viruses cause 300,000 -500,000 deaths worldwide every year 1 . There are only two classes of drugs currently approved by the Food and Drug Administration (FDA) for influenza prophylaxis and treatment in humans: neuraminidase (NA) inhibitors (e.g., oseltamivir) and blockers of the M2 ion channel (e.g., amantadine); however, the emergence of drug-resistant virus variants is an increasing concern. Vaccination, therefore, remains the best medical option to protect humans against IAVs infections. To date, three types of influenza vaccines licensed by the FDA for human use are available: recombinant viral hemagglutinin (HA) protein vaccines, inactivated influenza vaccines (IIV), and liveattenuated influenza vaccines (LAIV) 5, 7 . The three vaccines are designed to induce adaptive immune response against the viral HA protein, the major target of neutralizing antibodies against IAVs.
Use of Small Vertebrate Animals
NOTE: The proper Personal Protection Equipment (PPE) is required for working with mice. Minimum requirements include disposable coveralls, shoe covers, head bonnet, mask, and gloves.
1. In accordance with the IACUC protocol, place a maximum of 5 mice per cage. Following IACUC protocol, euthanize mice with two methods of euthanasia (the second must be a physical method) to ensure that the animal is dead. NOTE: In the experiments in which IAV morbidity and mortality are evaluated, mice that lost 20% of their initial body weight were considered to have reached the experimental endpoint, and were euthanized with CO 2 , and cervical dislocation as the physical secondary method. This percentage of body weight may be different in other institutions. In the procedures where the mice lungs and nasal mucosa are collected after IAV infection, mice are euthanized with a lethal dose of 2,2,2-tribromoethanol (TBE), and by cutting the hepatic vein as the physical secondary method. Female 6-to-8-week-old C57BL/6 mice were purchased and maintained in the animal care facility at the University of Rochester School of Medicine and Dentistry under specific pathogen-free conditions.
Biosafety
NOTE: In this report, the IAVs used to infect mice are the common mouse-adapted laboratory strain of influenza A/Puerto Rico/8/34 H1N1 (PR8 WT) 22, 23 and a temperature sensitive LAIV variant, PR8 LAIV 8 . Perform all procedures that involve IAV infections (in vitro or in vivo), cell cultures, and biological samples, in a biological safety cabinet under biosafety level (BSL)-2 conditions. Utilize other BSL suits or containment conditions if highly virulent IAV strains are used.
1. Clean the biosafety cabinet with chlorine dioxide disinfectant before and after performing all the experimental procedures described in this manuscript. Sterilize all dissection material (scissors, scalpel and dissecting forceps) and the Dounce homogenizer before and after their use following proper IBC recommendations. Discard all material produced during the procedures under proper IBC and IACUC guidelines.
Intranasal Infection
1. Place the female 6-to-8-week-old C57BL/6 mice under specific pathogen-free conditions. Organize and label the mouse cages with the virus and dose used. Identify the mice in each cage using an ear punch code or with another approved method such as painting of the tails. Place a maximum of 5 mice per cage. 2. Prepare the dilution of IAV (Fluorescent Forming Units (FFU)/mouse) under aseptic conditions in a total volume of 30 µL/mouse in sterile 1x phosphate buffer saline (PBS). Maintain the virus inoculum on ice. Calculate the amount of IAV to add in the viral dilution with the formula: ((X FFU per mouse / 30 µL) x final volume) / stock viral titer. 3. Weigh the mice with a scale and record the weight of each mouse (Day 0). Hold the mouse in a dorsal position by picking it up by the scruff of the neck between the index finger and thumb. Hold the tail against the hand with the pinky finger. 4. Anesthetize the mouse intraperitoneally (i.p.) with 240 -250 mg/kg of TBE by inserting the needle in the caudal 2/3 of the right side of the abdomen. Pause briefly before withdrawing the needle. Return the mouse to the cage and wait 5 min. 5. Apply sterile ophthalmic ointment to the eyes to prevent dryness while the mouse is anesthetized. Check if the mouse is anesthetized by lack of pedal withdrawal reflex (i.e., toe pinch). If mice are not fully anesthetized they will cough up the virus. 6. When the mouse is fully anesthetized, place the mouse in dorsal recumbency. Put the pipet tip containing 30 µL of the virus inoculum in the nostril and slowly but constantly eject the solution. Be sure the mouse is inhaling the preparation by observing the inoculum drop disappearing. LAIV, and mock-infect one group (n = 5) with 1x sterile PBS as a negative control. Perform the i.n mouse infections as described in section 3. 1. Mouse bleeding by submandibular puncture 1. Fourteen days after immunization, collect the mice blood by submandibular bleeding using a 4 mm lancet 26 , or using another IACUC approved method.
1. Hold the mouse by picking it up by the scruff of the neck between the index finger and thumb. Hold the tail against the hand with the pinky finger to immobilize the mouse. 2. Put the mouse in a lateral position to see the cheek. Make the puncture at the juncture of the retro-orbital and submandibular veins with the jugular vein. Sink the lancet (4-mm) and recover the blood in a sterile tube (approximately 0.2 -0.4 mL/mouse are recovered). Apply pressure on the puncture with a sterile napkin for a few seconds. Place the mouse back into the cage. Calculate the amount of PR8 WT with the formula ((X MOI x n°cells) x final volume) / stock viral titer. 3. Aspirate the tissue culture medium from the MDCK cell plate and wash twice with 4 mL of 1x PBS. Add the viral inoculum (4 mL) and put the plate on a rocking platform for 1 h at RT to allow viral adsorption. Remove the viral inoculum with vacuum and add 8-10 mL of post-infection media containing 1 µg/mL of TPCK-treated trypsin. Incubate infected cells for 48 -72 h in a 33 °C or 37°C incubator with 5% CO 2 .
4. Detach the cells with the aid of a cell scraper and collect the cells and tissue culture medium with a pipet in a 15-mL tube.
Centrifuge the tube at 400 x g for 5 -10 min at RT. Aspirate the supernatant and resuspend the cell pellet in 1 mL of RIPA buffer and put the mix in a 1.5-mL sterile tube. Incubate on ice for 20-30 min. 5. Centrifuge the tube at 1,300 x g for 20 -30 min at 4 °C. Carefully, recover the supernatant. Store the cell extract in 100 µL aliquots at -20 °C. 6. Titrate the cell extracts as described by enzyme-linked immunosorbent assay (ELISA) before evaluating them for the presence of antibodies 9, 10, 11, 27 . Include cell extracts from mock-infected MDCK cells (prepared as indicated above) as a negative control. Incubate O/N (12 -18 h) in a 37 °C water bath. 2. Heat the serum samples at 56 °C for 30 min to inactivate the RDE. 3. Pre-determine the hemagglutination activity (HAU) of PR8 WT by standard HA assay 28 . Once the viral HAU is determined, dilute the viral stock to 8 HAU per 50 µL in 1x PBS. 4. Prepare 2-fold serial dilutions (12 dilutions) of RDE-treated sera in a 96-well V-bottom plate. Use one row for each serum sample (e.g., A1 to A12). 1. Add 25 µL of 1x PBS from A1 to A12 wells. Test each of the serum samples in one row. Add 25 µL of RDE-treated sera (1:5) to 25 µL of 1x PBS in the first well of the column (A1). The first serum dilution is 1:10. 2. Once all RDE-treated sera are added to the first column, (e.g., A1, B1, C1), use a multichannel pipet to mix the sera and 1x PBS by pipetting up and down. Transfer 25 µL of the diluted sera from the first column to the second column (e.g., from A1 to A2). Change the tips between dilutions and mix. 3. Repeat steps 5.3.1.4.2. until reaching the last column (e.g., A12, B12, C12). Discard the 25 µL from the last column, keeping the volume consistent in all the wells (25 µL). Include one row of wells containing only 25 µL of 1x PBS without any sera as a negative control. NOTE: The reciprocal value of this dilution is the HAI titer. The reciprocal value is multiplied by a factor of 20 to correct for the 1:20 dilution of the serum in the first row.
2. Virus microneutralization assay (VNA) (Figure 6) 1. The day before VNA, prepare MDCK cells in a 96-well plate to reach 80-90% confluence the next day as described in step 5.2.1.1. Prepare a dilution of PR8 WT in infection media to have 200 FFU/25 µL. 2. Inactivate the mouse sera at 56 °C for 1 h. Make 2-fold serial dilutions (12 dilution) per mouse sera in triplicate using a 96-well plate.
1. Add 40 µL of serum to 160 µL of infection media in the first well of the first row, (e.g., A1) (serum dilution 1:5). Mix by pipetting. Add 100 µL of infection media to the other wells (A2 to H12). 2. Transfer 100 µL from the first row to the second row to make 1:2 dilutions (e.g., from A1 to A2). Change tips between dilutions and mix by pipetting. Repeat this until the last row (e.g., A12). Discard 100 µL from the last row, keeping the volume consistent in all the wells (100 µL).
3. Add 100 µL of IAV dilution to all wells. Incubate 1 h at RT. Meanwhile, remove the tissue culture medium from the MDCK cells in the 96-well plate using a vacuum aspirator-multichannel adapter and wash twice with 100 µL/well of 1x PBS. 4. In each 96-well plate of MDCK cells, leave two rows for the controls. One row is the negative control (cells without virus and sera), and the other row is the positive control of infection (cells with virus in the absence of sera or sera from mock-infected mice). 5. Transfer 50 µL/well from the virus-antibody plate to the 96-well plates of MDCK cells. Put the plates on a rocking platform for 1 h at RT to allow viral adsorption. 6. Remove the virus-antibody inoculum using a vacuum aspirator-multichannel adapter and add 100 µL/well of post-infection media containing 1 µg/mL of TPCK-treated trypsin. 7. Incubate the cells for ~3 -4 days in a 33 °C or 37 °C incubator with 5% CO 2 until cytopathic effect (CPE) is observed in the positive control (infected cells in the absence of sera or with control serum). 8. Remove the tissue culture medium using a vacuum aspirator-multichannel adapter and add 100 µL/well of 0.1% crystal violet.
Incubate for 1 h at RT. Remove the crystal violet solution using a vacuum aspirator-multichannel adapter. Wash the wells 3 times with distilled water. Dry the plates at RT. 9. Calculate the VNA titers by identifying the highest dilution that retains a confluent cell monolayer of MDCK cells.
NOTE: The reciprocal value of this corresponding dilution is the neutralizing antibody titer. The reciprocal value is multiplied by a factor of 10 to correct the 1:10 dilution of the sera in the first well of the row. (Figure 3) 1. Vaccinate i.n. a group of female 6-to-8-week-old C57BL/6 mice (n = 11) with the PR8 LAIV dose to test (FFU/mouse) and mock-vaccinate another group of mice (n = 11) with 1x sterile PBS. Perform the mouse i.n. immunizations as previously described in section 3. 2. Fourteen days post-vaccination, bleed the mice and collect the sera as described in section 3. Analyze the presence of total and neutralizing antibodies against PR8 WT as described in section 5.1.1. 3. Fifteen days post-vaccination, measure and record the mouse body weight (Day 0). Challenge mice i.n. with a lethal dose of the PR8 WT (homologous challenge) as previously described in section 3. 4. Measure the body weight and survival (n = 5 / group) during 14 days after challenge to evaluate the morbidity and mortality produced by the PR8 WT challenge in vaccinated mice (section 4.1). 5. Recover mouse lungs and nasal mucosa (n = 3/day) at day 2 and day 4 post-challenge with PR8 WT. Homogenize and analyze the lungs and nasal mucosa as described in section 4.2 to assesses the viral replication of PR8 WT in vaccinated mice.
Evaluation of Protection Efficacy Vaccines

Representative Results
Characterization of viral pathogenesis in mice
The pathogenesis of IAV is related to the morbidity and mortality caused by its infection. These two parameters can be evaluated in mice easily: IAV morbidity is associated with body weight loss in infected mice and the percentage of survival will indicate the mortality rate (Figure 1) . The body weight and survival in IAV-infected mice are usually monitored daily for at least two weeks after infection 8, 9, 10, 29 . The survival data obtained can determine the MLD 50 that was calculated using the method of Reed and Muench 25 . Another indicator of IAV pathogenesis is related to viral replication in the lower (lungs) and in the upper (nasal mucosa) respiratory tract (Figure 1) . The information obtained with the viral titer in these organs corresponds to the morbidity and mortality values, and taken together provide a good indication of viral pathogenesis. It is known that IAV replication in mouse lungs peak between days 2 and 4 post-infection (p.i.), and so we recommended recovering these organs at days 2 and 4 p.i.
Figure 1: Characterization of IAV Pathogenesis in Mice:
IAV pathogenesis in mice is related to its morbidity (body weight loss) and mortality (% survival), and also to the ability of IAV to replicate in the upper (nasal mucosa) and lower (lungs) respiratory tract. Briefly, on Day 0 mice are weighed and anesthetized intraperitoneally with 2,2,2-tribromoethanol (TBE) before they are infected intranasally with IAV. From day 1 to day 14, mice are weighed daily to evaluate body weight loss (morbidity) and % survival (mortality) to calculate the mouse lethal dose 50 (MLD 50 ). On days 2 and day 4 post-infection, mice lungs and nasal mucosa are recovered and homogenized to evaluate viral replication. Mice experiments to characterize IAV pathogenesis using PR8 WT are performed under BSL-2 conditions. Please click here to view a larger version of this figure.
In Figure 2 , the data obtained in the evaluation of PR8 WT pathogenesis is represented. Four groups of 6-to-8-week-old C57BL/6 mice (n = 11) were infected i.n. with the indicated doses (10, 10 2 , 10 3 and 10 4 FFU/mouse) of PR8 WT. The body weight and survival of 5 mice per group were measured by 14 days p.i. (Figure 2A-B) . All mice immunized with 10 4 FFU of PR8 WT lost weight quickly (Figure 2A ) and all of them died at days 5 and 6 p.i. (Figure 2B ). Mice immunized with 10 3 FFU of PR8 WT lost body weight at later times p.i. (Figure 2A ) and they all died by days 7 and 8 p.i. (Figure 2B ). All mice immunized with 10 2 FFU of PR8 WT lost body weight (Figure 2A ) but only 2 of them died at day 9 p.i. (Figure   2B ). Finally, mice immunized with 10 FFU of PR8 WT did not lose weight (Figure 2A ) and all of them survived infection ( Figure 2B) . The MLD 50 of PR8 WT in this experiment calculated with the Reed and Muench method 25 was 1.5 x 10 2 FFU ( Figure 2C ).
To evaluate the PR8 replication in the upper and lower respiratory tract of mice infected i.n. with the indicated doses (10, 10
, and 10 4 FFU/ mouse), the lungs and nasal mucosa were recovered at days 2 and 4 p.i. (n = 3). After lung homogenization, the amount of virus present in this organ was analyzed by immunofluorescence assay (Figure 2D) . The viral titer detected in the lungs of the different mice groups was related with the dose used to immunize them: higher viral titers were detected in lungs of mice immunized with 10 4 FFU of PR8 WT at days 2 and 4 p.i., while lower viral titers were detected in the lungs of mice immunized with 10 FFU of PR8 WT. (Figure 3) . In the mouse model, 14 days after immunization, mice are bled to analyze the presence of antibodies against the total viral proteins by ELISA (Figure 4) , and the presence of neutralizing antibodies targeting the viral HA protein, which is usually analyzed by common serologic approaches, such as a HAI assay ( Figure  5 ) and/or a VNA (Figure 6 ). Figure 1 . Mice experiments to characterize safety, immunogenicity and protection efficacy of a LAIV candidate are performed under BSL-2 conditions. Other BSL suits or containment conditions may be required depending on the IAV strain used for the challenge of vaccinated mice. Please click here to view a larger version of this figure.
Evaluation of the humoral responses induced after vaccination
Humoral responses induced against IAV infection play an essential role in controlling viral infection. For this reason, it is very important to analyze the humoral responses elicited by IAV WT infections or by new IAV vaccines
To assess immunogenicity of PR8 LAIV, three groups of 6-to-8-week-old C57BL/6 mice (n = 5) were immunized with different doses (10   2   ,10   3   ,  and 10 4 FFU/mouse) of PR8 LAIV or mock vaccinated with 1x PBS as a negative control. Fourteen days after vaccination, mice sera were collected by submandibular bleeding 26 ( Figure 3) . Antibody responses against total viral proteins were evaluated by ELISA using a 1:200 dilution of cell extract of PR8-infected MDCK cells (Figure 4) . Each serum was analyzed individually. The results indicate that the sera from mice immunized with the higher dose (10 4 FFU) of PR8 LAIV had higher antibody titers against total PR8 proteins than the sera of mice immunized To analyze the presence of neutralizing antibodies in the mouse serum using the HAI assay, serial 2-fold dilutions of sera (previously inactivated at 56 °C) of each group of mice immunized with different doses (10 In Figure 6 , the data obtained in the evaluation of neutralizing antibodies in mouse sera by VNA is represented. 200 FFU of PR8 WT were mixed with serial 2-fold dilutions of sera (previously inactivated at 56 °C) from mice immunized with different doses (10 
Discussion
The mouse model of IAV is widely used for in vivo studies of IAV pathogenesis, immunogenicity and protection efficacy. The small size of mice makes them easy to manipulate and store as compared to other animal models such as ferrets or guinea pigs. Moreover, the ease in terms of animal cost, housing and reproduction allow their use in pre-clinical vaccination tests in which large numbers of animals are needed. Notably, since mice have been used in multiple research disciplines, several molecular and immunology murine reagents are available to facilitate their use for IAV studies. Furthermore, the minimal host variability and the presence of an immune system that is evolutionarily similar to that present in humans make them a robust small animal model for IAV studies. Finally, the study of host-viral protein interactions and their contribution to viral pathogenesis are currently feasible by the access to KO mice. However, beside the several advantages of using mice for IAV studies, they are not useful for IAV transmission studies. Therefore, ferrets or guinea pigs are more suitable animal models to study IAV transmission. Clinical symptoms in mice infected with IAV usually appear 2 -3 days post-infection, although this may vary depending on the mouse age, immune status, sex, genetic background and strain; as well as viral strain and dose used. Symptoms include anorexia, lethargy, huddling, ruffled fur, loss of body weight and death 16, 17 .
In this manuscript, we describe how to evaluate viral pathogenesis in mice infected i.n. with IAV by monitoring body weight loss (morbidity), percentage of survival (mortality) and by assessing viral replication in the upper (nasal mucosa) and lower (lungs) respiratory tract ( Figure 1 and Figure 2 ). The pathogenesis of IAV is a very important parameter not only in the context of new IAV strains but also in the safe implementation of LAIV vaccine candidates (Figure 3) . Seasonal IAVs and IAVs that infect other mammals (like horses, dogs or pigs) do not usually produce signs of disease in mice 11, 27 . In this case, the analysis of viral titers in the lungs or nasal mucosa of infected mice is the main parameter to evaluate viral pathogenesis of IAV strains. Once the lungs and nasal mucosa are collected, they are homogenized and the amount of virus present in these organs can be analyzed by plaque assay, immunofluorescence assay, tissue culture infectious dose 50 (TCID 50 ) or another validated method 8, 29 . We recommend evaluating viral titers using indirect immunofluorescence since the plaque assay requires a higher quantity of MDCK cells (6-well plate format) and, like the TCID 50 , more time (3 -4 days) is required to calculate viral titers. However, to perform the indirect immunofluorescence assay, it is necessary to have: 1) primary specific antibodies against an IAV protein (it is recommended to use an antibody against the IAV nucleoprotein, NP, since it is the most abundant viral protein produced during viral infection); 2) secondary antibodies conjugated to a fluorophore; and 3) a fluorescence microscope to count fluorescent positive infected cells.
Since the immune system of mice is evolutionarily similar to the immune system of humans 16 and because mice can elicit a strong and protective humoral response against IAV infection, the immunogenicity of IAVs (or vaccine candidates) can be easily evaluated by determining total (ELISA; Figure 4 ) and neutralizing (HAI, Figure 5 ) or VNA (Figures 6) antibody responses. To analyze the humoral responses after immunization, mice can be bled by different approved methods such as retro-orbital puncture, tail clip, saphenous vein puncture or submandibular puncture. We chose the submandibular puncture technique 26 because the procedure does not require the use of anesthesia and allows us to obtain an acceptable volume of blood for immunological studies; as opposed to the retro-orbital puncture, where mice should be anesthetized, and with the tail clip or saphenous vein puncture, where the blood volume recovered usually is low.
In this manuscript, we described how to evaluate the presence of antibodies against total viral proteins by ELISA using virus infected cell extracts. Since IAV infection induces a protective immunity mediated, mainly, by antibodies against the viral HA (the main antigenic viral target), it is highly recommended to assess the amount of specific antibodies induced against HA by ELISA using recombinant purified HA proteins 10 . To analyze the presence of neutralizing antibodies, both HAI and VNA methods are accepted but both have advantages and disadvantages. The HAI is rapid (2-3 h) and approved by the Center for Disease and Control (CDC) to evaluate the presence of IAV neutralizing antibodies 30 . The VNA is more time consuming (3-4 days) but is more specific since it evaluates only antibodies that can neutralize viral infection. Notably, the VNA has been shown to detect stalk-reactive HA neutralizing antibodies 31 , as well as NA neutralizing antibodies FFU. Moreover, the HAI assay can be problematic for detecting neutralizing antibodies against avian IAVs due to difficulty with interpreting results 33, 34, 35 . Additionally, VNA does not require the use of RBCs for the identification of influenza neutralizing antibodies.
Finally, we describe the experimental procedures to evaluate the three main aspects that have to be considered in developing new IAV vaccines (Figure 3 ): 1) safety: the vaccine must be safe and not produce disease; 2) immunogenicity: the vaccine must be immunogenic and induce both humoral and cellular protective responses; 3) protection efficacy: the vaccine must induce protection against challenge with WT homologous and/ or heterologous viruses. The mouse model is a good choice for the first screening of a new IAV vaccine in vivo because it can evaluate diverse vaccination schemes and conditions, including use of different adjuvants, antigen/vaccine dose, administration and broad protection against challenge with homologous or heterologous IAVs strains 16, 17 . However, before proceeding to human clinical trials, vaccine candidates should at a minimum be tested in a second in vivo model.
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